Q-omics provides the consensus-scored CYCSP29 profile across patient tissues and cancer cell-line models. CYCSP29 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, CYCSP29 is differentially expressed in 1, with the highest sampling consensus in KICH. Additionally, CYCSP29 RNA expression shows 7,640 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THYM, KICH, and GBM as cancer lineages where CYCSP29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCSP29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCSP29 survival associations across molecular data types. CYCSP29 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCSP29 RNA expression–survival associations across cancer types. High CYCSP29 expression shows unfavorable associations in THYM, ACC, MESO, KIRC, OV and DLBC. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for CYCSP29 RNA expression.
This table summarizes CYCSP29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CYCSP29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCSP29 shows higher tumor expression in KICH. The KICH box plot shows higher CYCSP29 RNA expression in tumor versus normal tissue (log2 FC = +0.029, t-test p = .044).
This table shows molecular features associated with CYCSP29 in patient tissues and cancer cell lines. In patient samples, CYCSP29 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
